BioTuesdays

Tag - Andrew Fein

Syros Logo
Markets

HCW ups Syros PT on optimism about AML data at ASH

H.C Wainwright raised its price target for Syros Pharmaceuticals (NASDAQ:SYRS) to $20 from $6, noting that the company’s tamibarotene “looks to shine during ASH ‘22” in December. The stock closed at $3.66 on Nov. 14...

November 15, 2022
Aileron Therapeutics Logo
Markets

HCW cuts Aileron Therapeutics PT to $1 from $2

H.C. Wainwright reduced its price target for Aileron Therapeutics (NASDAQ:ALRN) to $1 from $2, but maintained its “buy” rating, after the company reported “underwhelming” interim data from a Phase 1 study in non-small...

June 30, 2022
Theseus Logo
Markets

HCW starts Theseus Pharma at buy; PT $22

H.C. Wainwright launched coverage of Theseus Pharmaceuticals (NASDAQ:THRX) with a “buy” rating and price target of $22. The stock closed at $5.20 on June 29. “We believe pan-inhibition could be the key to success in...

June 30, 2022
Acumen Pharmaceuticals Logo
Markets

HCW starts Acumen Pharma at buy; PT $15

H.C. Wainwright initiated coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with a “buy” rating and $15 price target. The stock closed at $4.88 on June 29. Acumen is a clinical-stage biopharmaceutical company developing...

June 30, 2022
Amarin
Markets

Analysts downgrade Amarin; PTs cut to $3

Analysts for H.C. Wainwright and SVB Securities downgraded Amarin (NASDAQ:AMRN) to “neutral” from “ buy” and to “market perform” from “outperform,” respectively. Both analysts cut their prices targets to $3 from $10...

May 5, 2022
Foghorn Therapeutics
Markets

HCW starts Foghorn Therapeutics at buy; PT $25

H.C. Wainwright initiated coverage of Foghorn Therapeutics (NASDAQ:FHTX) with a “buy” rating and price target of $25. The stock closed at $13.68 on Nov. 19. Foghorn is a leader in the field of chromatin biology. The...

November 22, 2021
Sutra-Biopharma-Logo
Markets

HCW starts Sutro Biopharma at buy; PT $35

H.C. Wainwright initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and price target of $35. The stock closed at $18.73 on June 17. “We believe Sutro Biopharma can continue to be a standout performer...

June 17, 2021
Unity-Biotechnology
Markets

HCW starts UNITY Biotechnology at buy; PT $12

H.C. Wainwright launched coverage of UNITY Biotechnology (NASDAQ:UBX) with a “buy” rating and $12 price target. The stock closed at $4.56 on June 4. UNITY is focusing on therapeutics addressing diseases of aging, while...

June 7, 2021
Prothena
Markets

HCW starts Prothena at buy; PT $22

H.C. Wainwright launched coverage of Prothena (NASDAQ:PRTA) with a “buy” rating and price target of $22. The stock closed at $11.53 on Dec 4. Prothena is focused on protein-opathies affecting the central nervous system...

December 7, 2020